Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets

Corrado Pelaia(Azienda Ospedaliero Universitario Mater Domini), Giorgio Walter Canonica(Humanitas University), Claudia Crimi(Marconi University), Girolamo Pelaia(Magna Graecia University), Angelantonio Maglio(University of Salerno), Alessandro Vatrella(University of Salerno), Enrico Heffler(Humanitas University)
Frontiers in Pharmacology
March 8, 2022
10.3389/fphar.2022.851940
Cited by 157

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
|International Forum of Allergy & Rhinology|2018|549
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|428